Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

16th International Adenovirus Meeting

The International Adenovirus Meeting is the premier event dedicated exclusively to adenovirus research, covering every facet of its biology, pathology, and use in biotechnology. We’re [...]

Go to Top